ClinicalTrials.gg
Active, not recruitingNCT04835805Updated Sep 30, 2026

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

A Phase 1 interventional study of Belvarafenib and Cobimetinib in Melanoma, sponsored by Genentech, Inc.. Active, not recruiting at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Updated Sep 30, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing cobimetinib in Melanoma — 3 open to participants now, 6 under way, 1 of them phase 3. cobimetinib · Melanoma.

Enrollment
11th of 27
65 · median 45
Started
2021
the only one that year
Phase 1
5 of 27
none open now
Registered
24th of 27
by date
Lead sponsor
2 of 27
Genentech, Inc.

Among the 27 studies testing cobimetinib in Melanoma, this one is the 11th largest by enrollment, is the only one that started in 2021, is one of 5 in phase 1, and was the 24th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 27 studies testing cobimetinib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cobimetinib

cobimetinib: first FDA approval 2015 (COTELLIC), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing cobimetinib in Melanoma, or all of them as a file.
02

Study summary

This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

Read the detailed description

The study will evaluate three treatment regimens in three arms: a belvarafenib monotherapy arm (Belva arm); a belvarafenib plus cobimetinib arm (Belva + Cobi arm) in an initial dose-finding phase followed by an expansion phase and a belvarafenib plus cobimetinib plus nivolumab arm (Belva + Cobi + Nivo arm) in a run-in phase followed by an expansion phase.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Performance Status of 0 or 1
  • confirmed, (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III) cutaneous melanoma, that has progressed on or after treatment with or anti-PD-L1 therapy. Patients may have received up to two lines of systemic cancer therapy. Treatment with anti-PD-1/PD-L1 in the setting is acceptable. Patients must have progressed disease at study entry
  • Documentation of NRAS mutation-positive within 5 years prior to screening
  • Tumor specimen availability
  • Adequate hematologic and end-organ function
  • per v1.1

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a pan-RAF inhibitor
  • Treatment with systemic immunotherapy agents (e.g., anti-CTLA4, anti-PD(L)1, cytokine therapy, therapy, etc.) within 28 days prior to C1D1
  • Symptomatic, untreated, or actively progressing
  • History or signs/symptoms of cardiovascular disease
  • Known clinically significant liver disease
  • History of disease or immune deficiency
  • Prior treatment with a MEK inhibitor (cobimetinib arm)
  • History of or evidence of retinal pathology on ophthalmologic examination (cobimetinib arm)
  • History of immune-related AE attributed to prior anti-PD(L)1 therapy that resulted in permanent discontinuation of anti-PD(L)1 therapy (nivolumab arm)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Belvarafenib Monotherapy

    Twice daily (BID), continuous dosing.

    Drug: Belvarafenib

  • Experimental
    Belvarafenib Plus Cobimetinib

    Recommended dose (RD) and schedule of belvarafenib and cobimetinib selected based on the safety data, tolerability, pharmacokinetics, and anti-tumor activity tested in dose-finding phase followed by an expansion phase.

    Drug: Cobimetinib

  • Experimental
    Belvarafenib Plus Cobimetinib Plus Nivolumab

    Recommended dose (RD) and schedule of belvarafenib and cobimetinib plus nivolumab IV infusion every 4 weeks (Q4W) in a run-in phase followed by an expansion phase

    Drug: Nivolumab

Interventions

  • Twice daily (BID), continuous dosing

  • Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off

  • Once every 4 weeks (Q4W)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Dose Limiting Toxicity (DLTs)

    Time frame: 28 Days from Cycle 1, Day 1

  2. Percentage of Participants With Adverse Events

    Severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0

    Time frame: From Cycle 1, Day 1 Up to 4 Years

Secondary outcomes

  1. Objective response rate (ORR) according to RECIST v1.1

    Defined as the percentage of participants with a CR or PR on two consecutive occasions \>/= 4 weeks apart, as determined by the investigator according to RECIST v1.1

    Time frame: Up to Approximately 4 Years

  2. Progression free survival (PFS) according to RECIST v1.1

    Defined as the time from the first study treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1

    Time frame: Up to Approximately 4 Years

  3. Duration of response (DOR) according to RECIST v1.1

    Defined as the time from the first occurrence of a confirmed objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1

    Time frame: Up to Approximately 4 Years

  4. Overall survival (OS)

    Defined as the time from the first study treatment to death from any cause

    Time frame: Up to Approximately 4 Years

  5. Plasma concentration of belvarafenib at specified timepoints

    Time frame: Up to 30 Days After the Final Dose of Study Drug

  6. Plasma concentration of cobimetinib at specified timepoints

    Time frame: Up to 30 Days After the Final Dose of Study Drug

07

Study locations

20 sites
08

References and documents

Publications

  • Moschos SJ. War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging. Clin Cancer Res. 2022 Jul 15;28(14):2977-2979. doi: 10.1158/1078-0432.CCR-22-1256. PubMed 35587446 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 67 months is above that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 8, 2021
StartActual
May 13, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • University of Iowa · Iowa City, United States
  • Sarah Cannon Research Institute / Tennessee Oncology · Nashville, United States
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    2 sites added
    Show 2 added (2 United States)
    • University of Iowa · Iowa City, United States
    • Sarah Cannon Research Institute / Tennessee Oncology · Nashville, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04835805
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Apr 8, 2021
Start date
May 13, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belvarafenib · Cobimetinib

Start the discussion